Wobble Genomics to Present Full-Length mRNA Sequencing Data at AACR 2026

April 15, 2026
Wobble Genomics will present new research at the AACR Annual Meeting 2026 showcasing full-length mRNA sequencing from blood samples to support antibody-drug conjugate therapy selection in breast cancer.

Wobble Genomics will present new data at the American Association for Cancer Research (AACR) Annual Meeting 2026, highlighting its method for sequencing full-length mRNA from blood samples to aid in antibody-drug conjugate (ADC) therapy selection for breast cancer patients, announced in a press release.

The presentation, titled *Sequencing Full-Length mRNA in Whole Blood of Breast Cancer Patients for ADC Therapy Selection*, will take place on April 20, 2026, from 2:00–5:00 PM in Poster Section 45, Board #4, Poster #3843. The research is part of the “Liquid Biopsies: Circulating Nucleic Acids 3” session.

According to the company, the approach enables comprehensive mRNA profiling directly from blood, potentially reducing the need for invasive tissue biopsies. By capturing full-length transcripts, the data could help identify optimal treatment options and improve precision in therapy matching for patients undergoing complex treatments such as ADCs.

Wobble Genomics stated that it will engage with researchers, clinicians, and partners during the conference to discuss the application of its RNA sequencing technology in translational and therapeutic development.

We hope you enjoyed this article.

Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.

Also, consider following us on social media:

Healthcare & Life Sciences AI AI Brief AI Brief (X)

More from: Life Sciences

04/15
EmpiRx Health Launches Infusion Therapy Management Solution to Cut Costs
04/15
PrecisionLife and Ovation to Launch GLP-1 DNA Test by 2026
04/15
Cepheid and Oxford Nanopore Expand Partnership for Infectious Disease Genomics
04/14
Axxess AGILE 2026 Conference to Focus on Responsible AI in Home Care
04/14
Xtalks to Host Webinar on AI and Molecular Advances in Hematologic Cancer Drug Development

Subscribe to Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

AI Token Webinar

Industry analysis

2025 Global Business Services Agenda: Gen AI Takes Center Stage

The Hackett Group

This industry analysis by The Hackett Group explores the transformative impact of generative artificial intelligence (Gen AI) on global business services (GBS) in 2025. The study highlights the shift from exploration to acceleration of Gen AI initiatives, with 89% of executives advancing these projects to improve customer satisfaction, innovate products, and reduce costs. The report also discusses the challenges and strategies for successful Gen AI adoption, emphasizing the need for a technology-enabled operating model and the importance of reskilling the workforce.

Read more

You May Also Like